ARBUTUS BIOPHARMA CORPORATION— Sankey Diagram

Annual mode · period ending 2025-12-31 · SEC EDGAR

FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$95M
↓-28.2% -$37Mvs FY2024
Total Liabilities
$18M
↓-47.5% -$16Mvs FY2024
Equity
$77M
↓-21.4% -$21Mvs FY2024
Cash
$18M
↓-50.4% -$18Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
Reconciled values per the annual mode pipeline. Compare against SEC EDGAR filings.
Line itemFY2025FY2024
Total Assets$95M$132M
Current Assets$94M$127M
Cash$18M$36M
ST Investments$73M$86M
Receivables$1M$2M
Inventory$0$0
Other Current$2M$2M
Non-Current Assets$162K$4M
PPE$32K$3M
Goodwill$0$0
Intangibles$0$0
Investments$0$0
Other Non-Current$130K$1M
Total Liab+Eq$95M$132M
Current Liab.$6M$16M
Accounts Payable$0$0
Short-Term Debt$0$0
Deferred Revenue$0$8M
Other CL$6M$8M
Non-Current Liab.$12M$19M
Long-Term Debt$0$0
Other LT Liab.$12M$19M
Equity$77M$97M
Retained Earnings$1.38B$1.35B
Other Equity$0$0

QuarterCharts · SEC EDGAR data · ABUS · Comparing FY2025 vs FY2024